| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Maxwell Eisenbaum, Andrew Pearson, Camila Ortiz, Michael Mullan, Fiona Crawford, Joseph Ojo, Corbin Bachmeie. ApoE4 expression disrupts tau uptake, trafficking, and clearance in astrocytes. Glia. 2023-09-05. PMID:37668005. |
tauopathies are a collection of neurodegenerative diseases characterized by the accumulation of pathogenic aggregates of the microtubule-associated protein tau. |
2023-09-05 |
2023-09-07 |
mouse |
| Maxwell Eisenbaum, Andrew Pearson, Camila Ortiz, Michael Mullan, Fiona Crawford, Joseph Ojo, Corbin Bachmeie. ApoE4 expression disrupts tau uptake, trafficking, and clearance in astrocytes. Glia. 2023-09-05. PMID:37668005. |
despite the prevalence and diversity of tau astrogliopathy in tauopathies, the interactions between astrocytes and tau in the brain, and the influence of neurodegenerative genetic risk factors like the apolipoprotein e4 (apoe4) isoform, are largely unknown. |
2023-09-05 |
2023-09-07 |
mouse |
| Ruizhi Wang, Kun Ping Lu, Xiao Zhen Zho. Function and regulation of cis P-tau in the pathogenesis and treatment of conventional and nonconventional tauopathies. Journal of neurochemistry. 2023-08-28. PMID:37638382. |
conventional tauopathies are a group of disease characterized by tau inclusions in the brains, including alzheimer's disease (ad), pick's disease (pid), progressive supranuclear palsy (psp), corticobasal degeneration (cbd), and certain types of frontotemporal dementia (ftd), among which ad is the most prevalent. |
2023-08-28 |
2023-09-07 |
Not clear |
| George S Bloom, Andr\\xc3\\xa9s Norambuen. Dysregulation of mTOR by tau in Alzheimer's disease. Cytoskeleton (Hoboken, N.J.). 2023-08-28. PMID:37638691. |
interest in tau rose by the late 1980's, when it was shown to be the principal subunit of the neurofibrillary tangles (nfts) that accumulate in alzheimer's disease (ad) brain, and achieved new heights by the late 1990's, when numerous tau mutations were found to be highly penetrant for ad-related disorders that also are associated with nfts and came to be known as non-alzheimer's tauopathies. |
2023-08-28 |
2023-09-07 |
Not clear |
| Junhao Li, Amit Kumar, Bengt L\\xc3\\xa5ngstr\\xc3\\xb6m, Agneta Nordberg, Hans \\xc3\\x85gre. Insight into the Binding of First- and Second-Generation PET Tracers to 4R and 3R/4R Tau Protofibrils. ACS chemical neuroscience. 2023-08-28. PMID:37639522. |
in this study, we use multiple approaches, including docking, molecular dynamics, and metadynamics simulations, to investigate the binding mechanism of 10 first- and second-generations of pet tracers for psp tau and compare their binding in cortical basal degeneration (cbd) and ad tauopathies. |
2023-08-28 |
2023-09-07 |
Not clear |
| Zachary A Sorrentino, Giavanna Paterno, Benoit I Giasson, Julian E Bailes, John M Lee, Brandon Lucke-Wol. Differentiating pathologic tau in chronic traumatic encephalopathy (CTE) from other tauopathies: A potential antibody panel assessment. Journal of neuropathology and experimental neurology. 2023-08-28. PMID:37639632. |
differentiating pathologic tau in chronic traumatic encephalopathy (cte) from other tauopathies: a potential antibody panel assessment. |
2023-08-28 |
2023-09-07 |
Not clear |
| Mirjam Brackhan, Marina Arribas-Blazquez, Isabel Lastres-Becke. Aging, NRF2, and TAU: A Perfect Match for Neurodegeneration? Antioxidants (Basel, Switzerland). vol 12. issue 8. 2023-08-26. PMID:37627559. |
finally, we investigated the interconnection between nrf2 and tau and the relevance of alterations in the nrf2 signaling pathway in both primary and secondary tauopathies. |
2023-08-26 |
2023-09-07 |
Not clear |
| Esteban Cruz, Rebecca M Nisbet, J\\xc3\\xbcrgen G\\xc3\\xb6t. Break and accelerator-The mechanics of Tau (and amyloid) toxicity. Cytoskeleton (Hoboken, N.J.). 2023-08-26. PMID:37632370. |
aggregates of the microtubule-associated protein tau define more than a dozen primary tauopathies, and together with amyloid-\xce\xb2, the secondary tauopathy alzheimer's disease (ad). |
2023-08-26 |
2023-09-07 |
Not clear |
| Jennifer M Zupancic, Matthew D Smith, Hanna Trzeciakiewicz, Mary E Skinner, Sean P Ferris, Emily K Makowski, Michael J Lucas, Nikki McArthur, Ravi S Kane, Henry L Paulson, Peter M Tessie. Quantitative flow cytometric selection of tau conformational nanobodies specific for pathological aggregates. Frontiers in immunology. vol 14. 2023-08-25. PMID:37622125. |
the isolated nanobodies demonstrate conformational specificity for tau aggregates in brain samples from both a transgenic mouse model and human tauopathies. |
2023-08-25 |
2023-09-07 |
mouse |
| Gayatri Dev. The tauopathies. Handbook of clinical neurology. vol 196. 2023-08-24. PMID:37620072. |
tauopathies are a clinically and neuropathologically heterogeneous group of neurodegenerative disorders, characterized by abnormal tau aggregates. |
2023-08-24 |
2023-09-07 |
Not clear |
| Gayatri Dev. The tauopathies. Handbook of clinical neurology. vol 196. 2023-08-24. PMID:37620072. |
primary tauopathies are classified based on tau isoform and cell types where pathology predominates. |
2023-08-24 |
2023-09-07 |
Not clear |
| Francesco Panza, Vincenzo Solfrizzi, Antonio Daniele, Madia Lozupon. Passive tau-based immunotherapy for tauopathies. Handbook of clinical neurology. vol 196. 2023-08-24. PMID:37620094. |
tauopathies are heterogeneous clinicopathological entities characterized by abnormal neuronal and/or glial inclusions of the microtubule-binding protein tau. |
2023-08-24 |
2023-09-07 |
Not clear |
| Francesco Panza, Vincenzo Solfrizzi, Antonio Daniele, Madia Lozupon. Passive tau-based immunotherapy for tauopathies. Handbook of clinical neurology. vol 196. 2023-08-24. PMID:37620094. |
in secondary tauopathies, i.e., alzheimer's disease (ad), tau deposition can be observed, but tau may coexist with another protein, i.e., amyloid-\xce\xb2. |
2023-08-24 |
2023-09-07 |
Not clear |
| Bess Fros. Alzheimer's disease and related tauopathies: disorders of disrupted neuronal identity. Trends in neurosciences. 2023-08-17. PMID:37591720. |
in alzheimer's disease (ad) and related tauopathies, evidence suggests that pathogenic forms of tau drive neurodegeneration via neuronal cell cycle re-entry. |
2023-08-17 |
2023-09-07 |
human |
| Bess Fros. Alzheimer's disease and related tauopathies: disorders of disrupted neuronal identity. Trends in neurosciences. 2023-08-17. PMID:37591720. |
in this review, i delve into mechanistic parallels between tauopathies, cancer, and development, and highlight the role of tau in cancer and in the developing brain. |
2023-08-17 |
2023-09-07 |
human |
| Yu Zou, Bote Qi, Jingwang Tan, Lulu Guan, Qingwen Zhang, Yunxiang Sun, Fengjuan Huan. Deciphering the Inhibitory Mechanism of Naphthoquinone-Dopamine on the Aggregation of Tau Core Fragments PHF6* and PHF6. ACS chemical neuroscience. 2023-08-16. PMID:37585669. |
the formation of neurofibrillary tangles by abnormal aggregation of tau protein is considered to be an important pathological characteristic of tauopathies, including alzheimer's disease and chronic traumatic encephalopathy. |
2023-08-16 |
2023-09-07 |
Not clear |
| Itzhak Fische. Big tau: What, how, where and why. Cytoskeleton (Hoboken, N.J.). 2023-08-14. PMID:37578198. |
over the last 50\xe2\x80\x89years the different isoforms of tau proteins (45-60\xe2\x80\x89kda) have been a focus of research because of their roles in modulating the dynamic properties of microtubules shaping the structure and function of neurons but also becoming a center of attention in the pathology of neurodegeneration associated with tauopathies. |
2023-08-14 |
2023-08-16 |
Not clear |
| Itzhak Fische. Big tau: What, how, where and why. Cytoskeleton (Hoboken, N.J.). 2023-08-14. PMID:37578198. |
this perspective summarizes the progress so far in defining the structure and expression of big tau within and outside the nervous system, proposes a role for big tau in improving axonal transport in projecting axons, considers its potential in averting tau aggregation in tauopathies and highlights the need for further progress. |
2023-08-14 |
2023-08-16 |
Not clear |
| Nahuel N Foressi, Leandro Cruz Rodr\\xc3\\xadguez, M Soledad Cele. Heterotypic liquid-liquid phase separation of tau and \\xce\\xb1-synuclein: Implications for overlapping neuropathologies. Biochimica et biophysica acta. Proteins and proteomics. 2023-08-13. PMID:37574035. |
tauopathies and synucleinopathies are characterized by the aggregation of tau and \xce\xb1-synuclein (as) into amyloid structures, respectively. |
2023-08-13 |
2023-08-16 |
Not clear |
| Eliot J Davidowitz, Patricia Lopez, Heidy Jimenez, Leslie Adrien, Peter Davies, James G Mo. Small molecule inhibitor of tau self-association in a mouse model of tauopathy: A preventive study in P301L tau JNPL3 mice. PloS one. vol 18. issue 8. 2023-08-09. PMID:37556474. |
this study was performed in jnpl3 mice, which are representative of inherited forms of 4-repeat tauopathies with the p301l tau mutation (e.g., progressive supranuclear palsy and frontotemporal dementia). |
2023-08-09 |
2023-08-16 |
mouse |